Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Glecirasib

Copy Product Info
😃Good
Catalog No. T78651Cas No. 2657613-87-9
Alias KRAS G12C inhibitor 36, JAB-21822, JAB21822, JAB-21000, JAB21000

Glecirasib (JAB-21822) is an orally active KRAS G12C inhibitor that selectively binds to and inhibits the activity of KRAS G12C mutants, thereby inhibiting KRAS G12C-dependent signaling. In animal models, KRAS G12C inhibitor 36 showed a favorable safety profile and potential to inhibit tumor growth.

Glecirasib

Glecirasib

Copy Product Info
😃Good
Purity: 99.7%
Catalog No. T78651Alias KRAS G12C inhibitor 36, JAB-21822, JAB21822, JAB-21000, JAB21000Cas No. 2657613-87-9
Glecirasib (JAB-21822) is an orally active KRAS G12C inhibitor that selectively binds to and inhibits the activity of KRAS G12C mutants, thereby inhibiting KRAS G12C-dependent signaling. In animal models, KRAS G12C inhibitor 36 showed a favorable safety profile and potential to inhibit tumor growth.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$113-In Stock
5 mg$278-In Stock
10 mg$419-In Stock
25 mg$637-In Stock
50 mgPreferential-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.7%
Appearance:Solid
Color:Yellow
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Glecirasib (JAB-21822) is an orally active KRAS G12C inhibitor that selectively binds to and inhibits the activity of KRAS G12C mutants, thereby inhibiting KRAS G12C-dependent signaling. In animal models, KRAS G12C inhibitor 36 showed a favorable safety profile and potential to inhibit tumor growth.
Targets&IC50
KRas (G12C):1.6 nM
In vivo
Methods: Glecirasib (10 mg/kg, oral, once a day, 3 weeks) was used to treat NCI-H1373 xenograft mice, and the tumor growth and body weight growth in the mice were observed.
Results: Glecirasib inhibited tumor growth in the NCI-H1373 xenograft mouse model and had no significant effect on the body weight of the mice, indicating high safety. [1-3]
SynonymsKRAS G12C inhibitor 36, JAB-21822, JAB21822, JAB-21000, JAB21000
Chemical Properties
Molecular Weight640.03
FormulaC31H26ClF4N7O2
Cas No.2657613-87-9
SmilesN#CC=1C(=O)N(C=2N=C(C(Cl)=CC2C1N3CCN(C(=O)C=C)CC3)C=4C(F)=C(F)C(F)=C(F)C4N)C=5C(=NC=CC5C)C(C)C
Storage & Solubility Information
Storagestore at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy Glecirasib | purchase Glecirasib | Glecirasib cost | order Glecirasib | Glecirasib chemical structure | Glecirasib in vivo | Glecirasib formula | Glecirasib molecular weight